Glucagon-Like Peptide-1 Receptor Agonists and their Influence on Renal Metabolism

Chronic kidney disease represents a major global health burden, particularly among individuals with type 2 diabetes mellitus. The interplay between hyperglycemia, hypertension, and metabolic dysregulation accelerates renal injury through complex hemodynamic and inflammatory pathways. Traditional therapies have focused on glycemic and blood pressure control; however, recent pharmacological advances have expanded the therapeutic landscape [1]. Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs), initially developed as antihyperglycemic agents, have demonstrated significant cardiovascular and renal benefits. These agents mimic endogenous Glucagon-Like Peptide-1 (GLP-1), a gut-derived incretin hormone that enhances glucose-dependent insulin secretion while suppressing glucagon release. Beyond these actions, GLP-1 receptors are expressed in multiple tissues, including the kidney, where they mediate direct and indirect effects [2]. GLP-1 receptors are expressed in renal tubular and vascular tissues, particularly in proximal tubular cells and renal vasculature. This distribution supports both tubular and vascular mechanisms of action. Experimental studies have shown that receptor activation leads to intracellular cyclic Adenosine Monophosphate (cAMP) accumulation and activation of Protein Kinase A (PKA), influencing sodium handling and cellular metabolism [2].

Effects on renal hemodynamics

GLP-1 RAs exert favorable effects on renal hemodynamics through multiple pathways.

Natriuresis and tubular effects

One of the key mechanisms is inhibition of the Sodium- Hydrogen Exchanger 3 (NHE3) in the proximal tubule, leading to increased sodium excretion, reduced extracellular fluid volume and decreased blood pressure [2].

Glomerular hemodynamics

GLP-1 RAs may reduce intraglomerular pressure through modulation of renal vascular tone and improvement of endothelial nitric oxide availability. These effects help mitigate hyperfiltration, a hallmark of early diabetic nephropathy [2].

Metabolic effects in renal tissue

Mitochondrial function: GLP-1 RAs improve mitochondrial biogenesis and function through activation of Adenosine Monophosphate-Activated Protein Kinase (AMPK) and upregulation of peroxisome Proliferator-activated Receptor-Gamma Coactivator- 1alpha (PGC-1α). This results in improved energy homeostasis and reduced cellular stress [2].

Lipid metabolism

Renal lipotoxicity is a key contributor to chronic kidney disease progression. GLP-1 RAs reduce lipid accumulation in renal cells, enhance fatty acid oxidation and decrease ectopic lipid deposition [2].

Glucose handling

Although Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors dominate this pathway, GLP-1 RAs contribute by improving systemic glycemic control and reducing glucotoxicity [1].

Anti-inflammatory and antioxidant effects

Chronic inflammation and oxidative stress are central to chronic kidney disease progression. GLP-1 RAs suppress Nuclear Factor Kappa B (NF-kB) signaling, reduce pro-inflammatory cytokines [Tumor Necrosis Factor Alpha (TNF-α), Interleukin-6 (IL-6)] and decrease Reactive Oxygen Species (ROS) production. These actions collectively protect renal structures from progressive damage [2].

Sirtuin 1 (SIRT1)-mediated metabolic regulation

Recent experimental evidence indicates that part of the pleiotropic effects of GLP-1 RAs may involve activation of the Nicotinamide Adenine Dinucleotide (NAD⁺)-dependent deacetylase SIRT1, a key regulator of cellular metabolism, mitochondrial homeostasis, oxidative stress, inflammation and aging [3,4]. SIRT1 modulates several downstream targets, including peroxisome Proliferator-Activated Receptor Gamma Coactivator-1 Alpha (PGC-1α), Forkhead Box O (FOXO) transcription factors, Nuclear Factor Kappa B (NF-κB) and p53, thereby promoting mitochondrial biogenesis, improving energy metabolism and attenuating inflammatory responses [3,4]. Experimental studies suggest that GLP-1 receptor activation may enhance AMP-Activated Protein Kinase (AMPK)-SIRT1 signaling, contributing to improved mitochondrial function, increased fatty acid oxidation and reduced oxidative stress. Experimental evidence with exenatide has demonstrated SIRT1-dependent metabolic effects, whereas renal protective mechanisms are supported by experimental and translational studies investigating the role of SIRT1 in kidney disease [4-6].

Cardiovascular outcome trials

Recent trials have demonstrated reduction in albuminuria, slower decline in estimated glomerular filtration rate and cardiovascular risk reduction [7-10].

Notable studies include

Researching Cardiovascular Events with a Weekly INcretin in Diabetes - REWIND (dulaglutide), SUSTAIN-6 (semaglutide) and LEADER (liraglutide) [8-10].

Dedicated renal outcomes

The FLOW trial (2024) provided strong evidence of kidney protection with semaglutide, showing reduced progression to kidney failure and lower risk of sustained estimated glomerular filtration rate decline [11].

Comparison with SGLT2 inhibitors

while SGLT2 inhibitors remain the first-line nephroprotective agents, GLP-1 RAs offer greater weight reduction, superior glycemic control and complementary cardiovascular benefits. Combination therapy is increasingly recommended [1].

Therapeutic implications

GLP-1 RAs are particularly beneficial in patients with type 2 diabetes mellitus and obesity, early-stage chronic kidney disease and high cardiovascular risk. They may be used alongside SGLT2 inhibitors and Renin-Angiotensin-Aldosterone System (RAAS) blockers [1].

Future directions

Emerging research areas include dual agonists (GLP-1/GIP), precision medicine approaches and direct renal-targeted therapies. Further trials are needed to clarify long-term renal outcomes [7- 11].

GLP-1 receptor agonists represent a significant advancement in the management of cardiorenal-metabolic disease. Their multifaceted effects on renal metabolism, inflammation, and hemodynamics provide a strong rationale for their use in chronic kidney disease prevention and treatment. As evidence continues to evolve, these agents are likely to play an increasingly central role in nephrology [7].

1. Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, et al. (2022) Management of hyperglycemia in type 2 diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 45(11): 2753-2786.
2. Muskiet MHA, Tonneijck L, Smits MM, Van Baar MJB, Kramer MHH, et al. (2017) GLP-1 and the kidney: From physiology to pharmacology and outcomes in diabetes. Nat Rev Nephrol 13(10): 605-628.
3. Cantó C, Menzies KJ, Auwerx J (2015) NAD(+) Metabolism and the control of energy homeostasis: A balancing act between mitochondria and the nucleus. Cell Metab 22(1): 31-53.
4. Kitada M, Kume S, Takeda-Watanabe A, Kanasaki K, Koya D (2013) Sirtuins and renal diseases: Relationship with aging and diabetic nephropathy. Clin Sci (Lond) 124(3): 153-164.
5. Xu F, Li Z, Zheng X, Liu H, Liang H, et al. (2014) SIRT1 mediates the effect of GLP-1 receptor agonist exenatide on ameliorating hepatic steatosis. Diabetes 63(11): 3637-3646.
6. Zhang Q, Wang J, Hu X, Lu W, Cao Y, et al. (2025) GLP-1RAs regulate lipid metabolism and induce autophagy through AMPK/SIRT1 pathway to improve NAFLD. Prostaglandins Other Lipid Mediat 178: 106987.
7. American Diabetes Association Professional Practice Committee (2024) Chronic kidney disease and risk management: Standards of care in diabetes-2024. Diabetes Care 47(Suppl 1): S219-S230.
8. Mann JFE, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, et al. (2017) Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 377(9): 839-848.
9. Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, et al. (2019) Dulaglutide and renal outcomes in type 2 diabetes: An exploratory analysis of the REWIND randomized, placebo-controlled trial. Lancet 394(10193): 131-138.
10. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, et al. (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375(19): 1834-1844.
11. Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, et al. (2024) Effects of semaglutide on chronic kidney disease in patients with type 2 Diabetes. N Engl J Med 391(2): 109-121.